New filing

Ozempic Blindness Lawsuit Alleges Novo Nordisk Concealed NAION Risks

New filing from the mass tort press

Headline as published by AboutLawsuits.com on Oct 30, 2026; collected by the wire Oct 30, 2026, 2:15 PM ET.

Read at AboutLawsuits.com

Coverage

  1. AboutLawsuits.com Mass tort press

    Ozempic Blindness Lawsuit Alleges Novo Nordisk Concealed NAION Risks

Named in this story

Topics

Explore the named firms, organizations and MDL dockets above. Sources and method

MDL No. 3094

GLP-1 Receptor Agonists

IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation

Transferee judge
Karen S. Marston
Court
Eastern District of Pennsylvania
Actions pending
4,025

Per the JPML pending-dockets report of October 1, 2026.

MDL No. 3163

GLP-1 Vision Loss (NAION)

IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation

Transferee judge
Karen S. Marston
Court
Eastern District of Pennsylvania
Actions pending
247

Per the JPML pending-dockets report of October 1, 2026.